Primary objective: To demonstrate the clinical efficacy of otamixaban (dose effect via 5 intravenous [IV] regimens) in patients with moderate-to-high-risk non-STE ACS and planned early invasive strategy.Secondary objectives: To evaluate safety and assess pharmacokinetics (PK) and pharmacodynamics (PD).